EU/3/09/684: Orphan designation for the treatment of pancreatic cancer

Masitinib mesilate

Table of contents


On 28 October 2009, orphan designation (EU/3/09/684) was granted by the European Commission to AB Science, France, for masitinib mesylate for the treatment of pancreatic cancer.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 2 September 2009 recommending the granting of this designation.

Key facts

Active substance
Masitinib mesilate
Intended use
Treatment of pancreatic cancer
Orphan designation status
EU designation number
Date of designation
AB Science
3, avenue George V
75008 Paris
Tel. +33 1472 02311
Fax +33 1472 02411

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating